Drug Profile
LY 3202626
Alternative Names: LY-3202626Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Singapore (PO)
- 06 Nov 2019 Chemical structure information added
- 14 Jul 2019 Efficacy data from a phase II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2019)